Your browser doesn't support javascript.
loading
The evidence-based role of catecholaminergic PET tracers in Neuroblastoma. A systematic review and a head-to-head comparison with mIBG scintigraphy.
Piccardo, Arnoldo; Treglia, Giorgio; Fiz, Francesco; Bar-Sever, Zvi; Bottoni, Gianluca; Biassoni, Lorenzo; Borgwardt, Lise; de Keizer, Bart; Jehanno, Nina; Lopci, Egesta; Kurch, Lars; Massollo, Michela; Nadel, Helen; Roca Bielsa, Isabel; Shulkin, Barry; Vali, Reza; De Palma, Diego; Cecchin, Diego; Santos, Ana Isabel; Zucchetta, Pietro.
Afiliación
  • Piccardo A; Department of Nuclear Medicine, E.O. "Ospedali Galliera", Mura Delle Cappuccine 14, 16128, Genoa, Italy. arnoldo.piccardo@galliera.it.
  • Treglia G; Clinic of Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
  • Fiz F; Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
  • Bar-Sever Z; Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland.
  • Bottoni G; Department of Nuclear Medicine, E.O. "Ospedali Galliera", Mura Delle Cappuccine 14, 16128, Genoa, Italy.
  • Biassoni L; Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital, Tübingen, Germany.
  • Borgwardt L; Department of Nuclear Medicine, Schneider Children's Medical Center, Tel Aviv University, Tel Aviv, Israel.
  • de Keizer B; Department of Nuclear Medicine, E.O. "Ospedali Galliera", Mura Delle Cappuccine 14, 16128, Genoa, Italy.
  • Jehanno N; Great Ormond Street Hospital for Children, NHS Foundation Trust, London, UK.
  • Lopci E; Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Kurch L; Department of Nuclear Medicine and Radiology, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Massollo M; Department of Nuclear Medicine, Institut Curie Paris, Paris, France.
  • Nadel H; Nuclear Medicine Unit, IRCCS-Humanitas Research Hospital, Rozzano, Milano, Italy.
  • Roca Bielsa I; Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany.
  • Shulkin B; Department of Nuclear Medicine, E.O. "Ospedali Galliera", Mura Delle Cappuccine 14, 16128, Genoa, Italy.
  • Vali R; Department of Pediatric Nuclear Medicine, Lucile Packard Children's Hospital of Stanford (CA), Palo Alto, USA.
  • De Palma D; Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Cecchin D; St Jude Children's Research Hospital, Memphis, TN, USA.
  • Santos AI; Division of Nuclear Medicine, Department of Diagnostic Imaging, The Hospital for Sick Children of Toronto, Toronto, Canada.
  • Zucchetta P; Nuclear Medicine Unit, Ospedale Di Circolo of Varese, Varese, Italy.
Eur J Nucl Med Mol Imaging ; 51(3): 756-767, 2024 Feb.
Article en En | MEDLINE | ID: mdl-37962616
BACKGROUND: Molecular imaging is pivotal in staging and response assessment of children with neuroblastoma (NB). [123I]-metaiodobenzylguanidine (mIBG) is the standard imaging method; however, it is characterised by low spatial resolution, time-consuming acquisition procedures and difficult interpretation. Many PET catecholaminergic radiotracers have been proposed as a replacement for [123I]-mIBG, however they have not yet made it into clinical practice. We aimed to review the available literature comparing head-to-head [123I]-mIBG with the most common PET catecholaminergic radiopharmaceuticals. METHODS: We searched the PubMed database for studies performing a head-to-head comparison between [123I]-mIBG and PET radiopharmaceuticals including meta-hydroxyephedrine ([11C]C-HED), 18F-18F-3,4-dihydroxyphenylalanine ([18F]DOPA) [124I]mIBG and Meta-[18F]fluorobenzylguanidine ([18F]mFBG). Review articles, preclinical studies, small case series (< 5 subjects), case reports, and articles not in English were excluded. From each study, the following characteristics were extracted: bibliographic information, technical parameters, and the sensitivity of the procedure according to a patient-based analysis (PBA) and a lesion-based analysis (LBA). RESULTS: Ten studies were selected: two regarding [11C]C-HED, four [18F]DOPA, one [124I]mIBG, and three [18F]mFBG. These studies included 181 patients (range 5-46). For the PBA, the superiority of the PET method was reported in two out of ten studies (both using [18F]DOPA). For LBA, PET detected significantly more lesions than scintigraphy in seven out of ten studies. CONCLUSIONS: PET/CT using catecholaminergic tracers shows superior diagnostic performance than mIBG scintigraphy. However, it is still unknown if such superiority can influence clinical decision-making. Nonetheless, the PET examination appears promising for clinical practice as it offers faster image acquisition, less need for sedation, and a single-day examination.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Radiofármacos / Neuroblastoma Tipo de estudio: Systematic_reviews Límite: Child / Humans Idioma: En Revista: Eur J Nucl Med Mol Imaging Asunto de la revista: MEDICINA NUCLEAR Año: 2024 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Radiofármacos / Neuroblastoma Tipo de estudio: Systematic_reviews Límite: Child / Humans Idioma: En Revista: Eur J Nucl Med Mol Imaging Asunto de la revista: MEDICINA NUCLEAR Año: 2024 Tipo del documento: Article País de afiliación: Italia